| Autor: |
Sheila L, Stadler, Thomas J, Cook |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
The American journal of managed care. 23 |
| ISSN: |
1936-2692 |
| Popis: |
In patients with hypercholesterolemia who have atherosclerotic cardiovascular disease and/or familial hypercholesterolemia, a new class of drugs may be helpful in reducing serum levels of low-density lipoprotein cholesterol (LDL-C) beyond maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower LDL-C through a different mechanism of action than standard cholesterol-lowering therapies. Currently approved PCSK9 inhibitors are the monoclonal antibodies alirocumab and evolocumab. Although the drugs produce substantial reductions in LDL-C, cost issues and efficacy in preventing cardiovascular events should be evaluated when considering the adoption of PCSK9 inhibitors in the managed care setting. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
